Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys To Get Clinical Trial Milestone Payment From Centocor Ortho
As part of the Centocor Ortho Biotech collaboration in 2007, a HuCAL antibody became the first from MorphoSys to be developed in two different therapeutic areas – oncology
As part of the Centocor Ortho Biotech collaboration in 2007, a HuCAL antibody became the first from MorphoSys to be developed in two different therapeutic areas – oncology
Quotient Bioresearch’s The Old Glassworks is expected to produce radiolabelled compounds for use in both pre-clinical and clinical settings, for its pharmaceutical, biotechnology and agrochemical clients, offering a
Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in
Mead Johnson and Martek said that DHA and ARA are fatty acids important to infant development and growth. Clinical studies have demonstrated benefits for infants receiving DHA and
Ganciclovir for injection is an antiviral drug, which is used for the treatment of Cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), as
Novo Nordisk has been in discussion with the FDA regarding further progression of the development programme investigating the potential of Liraglutide within obesity. Based on the feedback from
OrbusNeich said that, in the investigator-initiated, single center, all-comers POTENT (Paclitaxel-eluting balloon and bio-engineered progenitor cell-attracting stainless steel stent in percutaneous treatment of coronary artery stenosis) registry, 32%
Incline is developing an investigational product candidate intended to provide patient-controlled analgesia for adult inpatients requiring opioids following surgery, called IONSYS (fentanyl iontophoretic transdermal system). IONSYS is a
The alliance valued over $750m, and includes a $25m upfront fee, a $10m future equity investment subject to mutual agreement on company valuation, and annual research support for
Sun Pharma said that, as per the terms of the settlement agreement, it is expected to be able to launch generic versions of 25mg/100mg/200mg and 37.5mg/150mg/200mg strengths of